MX2017011577A - Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf). - Google Patents
Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf).Info
- Publication number
- MX2017011577A MX2017011577A MX2017011577A MX2017011577A MX2017011577A MX 2017011577 A MX2017011577 A MX 2017011577A MX 2017011577 A MX2017011577 A MX 2017011577A MX 2017011577 A MX2017011577 A MX 2017011577A MX 2017011577 A MX2017011577 A MX 2017011577A
- Authority
- MX
- Mexico
- Prior art keywords
- tnf
- inhibitors
- heterocyclic compounds
- compounds useful
- compounds
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract 1
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134800P | 2015-03-18 | 2015-03-18 | |
| PCT/US2016/022742 WO2016149439A1 (en) | 2015-03-18 | 2016-03-17 | Heterocyclic compounds useful as inhibitors of tnf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017011577A true MX2017011577A (es) | 2017-10-26 |
Family
ID=55640934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017011577A MX2017011577A (es) | 2015-03-18 | 2016-03-17 | Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf). |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10112944B2 (enExample) |
| EP (1) | EP3271362B1 (enExample) |
| JP (1) | JP6779899B2 (enExample) |
| KR (1) | KR102696304B1 (enExample) |
| CN (1) | CN107567450B (enExample) |
| AU (1) | AU2016233202A1 (enExample) |
| BR (1) | BR112017019605A2 (enExample) |
| CA (1) | CA2980161A1 (enExample) |
| EA (1) | EA201792054A1 (enExample) |
| ES (1) | ES2803650T3 (enExample) |
| IL (1) | IL254430A0 (enExample) |
| MX (1) | MX2017011577A (enExample) |
| SG (1) | SG11201707473VA (enExample) |
| WO (1) | WO2016149439A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016233288A1 (en) | 2015-03-18 | 2017-11-09 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
| BR112017019731A2 (pt) | 2015-03-18 | 2018-05-22 | Bristol-Myers Squibb Company | compostos heterocíclicos tricíclicos úteis como inibidores de tnf |
| EP3294726A1 (en) | 2015-04-17 | 2018-03-21 | AbbVie Inc. | Indazolones as modulators of tnf signaling |
| EP3286195A1 (en) | 2015-04-17 | 2018-02-28 | AbbVie Inc. | Indazolones as modulators of tnf signaling |
| AR104291A1 (es) | 2015-04-17 | 2017-07-12 | Abbvie Inc | Moduladores tricíclicos de la señalización por tnf |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| WO2017023902A1 (en) | 2015-08-03 | 2017-02-09 | Bristol-Myers Squibb Company | Cyclic compounds useful as modulators of tnf alpha |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4391806A (en) * | 1982-07-12 | 1983-07-05 | The Dow Chemical Company | Substituted tetrahydropyridazino-(1,6-A)benzimidazoles and use as bronchodilators |
| ATE238998T1 (de) | 1997-02-25 | 2003-05-15 | Us Gov Health & Human Serv | Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore |
| JPWO2003064422A1 (ja) | 2002-01-31 | 2005-05-26 | 第一製薬株式会社 | イミダゾ［１，２−ａ］ピリジン誘導体 |
| WO2004050035A2 (en) | 2002-12-03 | 2004-06-17 | Isis Pharmaceuticals, Inc. | Benzimidazoles and analogs thereof as antivirals |
| US20050124638A1 (en) | 2003-12-08 | 2005-06-09 | Swayze Eric E. | Benzimidazoles and analogs thereof as antivirals |
| WO2008072682A1 (ja) * | 2006-12-15 | 2008-06-19 | Daiichi Sankyo Company, Limited | イミダゾ［１，２－ｂ］ピリダジン誘導体 |
| US20110009403A1 (en) | 2007-10-05 | 2011-01-13 | S*Bio Pte Ltd. | 2-morpholinylpurines as inhibitors of pi3k |
| JP2009227599A (ja) | 2008-03-21 | 2009-10-08 | Daiichi Sankyo Co Ltd | イミダゾピリダジン誘導体 |
| CN101717397B (zh) | 2008-10-09 | 2012-11-28 | 中国科学院上海药物研究所 | 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物 |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| WO2012148550A1 (en) | 2011-02-25 | 2012-11-01 | Myrexis, Inc. | Prodrugs of therapeutic compounds |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| WO2013186229A1 (en) * | 2012-06-11 | 2013-12-19 | Ucb Pharma S.A. | Tnf -alpha modulating benzimidazoles |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| EP2872508B1 (en) * | 2012-07-13 | 2018-08-29 | UCB Biopharma SPRL | Imidazopyridine derivatives as modulators of tnf activity |
| WO2014072261A1 (en) * | 2012-11-07 | 2014-05-15 | F. Hoffmann-La Roche Ag | Triazolo compounds |
| WO2014080241A1 (en) * | 2012-11-21 | 2014-05-30 | Piramal Enterprises Limited | Imidazopyridine compounds and uses thereof |
| WO2015008611A1 (ja) | 2013-07-18 | 2015-01-22 | 株式会社 村田製作所 | 積層型インダクタ素子の製造方法 |
| GB201321742D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321735D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321744D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| JP6469692B2 (ja) | 2013-12-09 | 2019-02-13 | ユーシービー バイオファルマ エスピーアールエル | Ｔｎｆ活性のモジュレーターとしてのイミダゾピリジン誘導体 |
| GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321741D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321739D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| RU2685234C1 (ru) | 2013-12-09 | 2019-04-17 | Юсб Байофарма Спрл | Конденсированные бициклические гетероароматические производные в качестве модуляторов активности tnf |
| GB201321743D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| TW201629063A (zh) | 2014-10-06 | 2016-08-16 | 標誌製藥公司 | 經取代胺基嘌呤化合物、其組合物及用其之治療方法 |
| AU2016233288A1 (en) | 2015-03-18 | 2017-11-09 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
| BR112017019731A2 (pt) | 2015-03-18 | 2018-05-22 | Bristol-Myers Squibb Company | compostos heterocíclicos tricíclicos úteis como inibidores de tnf |
-
2016
- 2016-03-17 BR BR112017019605A patent/BR112017019605A2/pt not_active Application Discontinuation
- 2016-03-17 US US15/558,724 patent/US10112944B2/en active Active
- 2016-03-17 SG SG11201707473VA patent/SG11201707473VA/en unknown
- 2016-03-17 MX MX2017011577A patent/MX2017011577A/es unknown
- 2016-03-17 EP EP16712647.3A patent/EP3271362B1/en active Active
- 2016-03-17 EA EA201792054A patent/EA201792054A1/ru unknown
- 2016-03-17 CN CN201680026732.5A patent/CN107567450B/zh active Active
- 2016-03-17 WO PCT/US2016/022742 patent/WO2016149439A1/en not_active Ceased
- 2016-03-17 CA CA2980161A patent/CA2980161A1/en not_active Abandoned
- 2016-03-17 ES ES16712647T patent/ES2803650T3/es active Active
- 2016-03-17 AU AU2016233202A patent/AU2016233202A1/en not_active Abandoned
- 2016-03-17 JP JP2017548855A patent/JP6779899B2/ja active Active
- 2016-03-17 KR KR1020177029451A patent/KR102696304B1/ko active Active
-
2017
- 2017-09-11 IL IL254430A patent/IL254430A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102696304B1 (ko) | 2024-08-16 |
| US10112944B2 (en) | 2018-10-30 |
| JP2018512062A (ja) | 2018-05-10 |
| SG11201707473VA (en) | 2017-10-30 |
| CN107567450B (zh) | 2020-03-13 |
| EP3271362B1 (en) | 2020-04-22 |
| ES2803650T3 (es) | 2021-01-28 |
| BR112017019605A2 (pt) | 2018-05-08 |
| EP3271362A1 (en) | 2018-01-24 |
| KR20170129192A (ko) | 2017-11-24 |
| WO2016149439A1 (en) | 2016-09-22 |
| IL254430A0 (en) | 2017-11-30 |
| EA201792054A1 (ru) | 2018-01-31 |
| AU2016233202A1 (en) | 2017-11-09 |
| CN107567450A (zh) | 2018-01-09 |
| US20180072728A1 (en) | 2018-03-15 |
| JP6779899B2 (ja) | 2020-11-04 |
| CA2980161A1 (en) | 2016-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017011577A (es) | Compuestos heterociclicos utiles como inhibidores de factor de necrosis tumoral (tnf). | |
| HK1252623A1 (zh) | 可用作TNFα调节剂的杂环化合物 | |
| MX2017011433A (es) | Compuestos heterociclicos triciclicos utiles como inhibidores del factor de necrosis tumoral (tnf). | |
| MX2020005622A (es) | Compuestos de indol sustituidos con arilo y heteroarilo. | |
| EA202091480A1 (ru) | Аминоиндольные соединения, пригодные в качестве ингибиторов tlr | |
| PH12017502090A1 (en) | Heterocyclic amides as kinase inhibitors | |
| EA202091484A1 (ru) | 4-азаиндольные соединения | |
| MX2020005873A (es) | Compuestos de 6-azaindol. | |
| MX2020006014A (es) | Compuestos de diazaindol. | |
| MX2017011434A (es) | Compuestos heterociclicos triciclicos sustituidos. | |
| MX2017009571A (es) | Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer. | |
| MX385332B (es) | Moduladores de ror-gamma. | |
| EA201790766A1 (ru) | Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1 | |
| MX384721B (es) | Tratamiento del cáncer usando combinaciones de inhibidores de erk y raf. | |
| EA201691516A1 (ru) | Дигидропирролопиридиновые ингибиторы ror-гамма | |
| EA201791095A1 (ru) | Способ лечения рака | |
| EA202091477A1 (ru) | Замещенные соединения простых индольных эфиров | |
| EA201400333A1 (ru) | Бензонитрильные производные в качестве ингибиторов киназ | |
| EA201790170A1 (ru) | Терапевтические соединения-ингибиторы | |
| MX2018001173A (es) | Compuestos ciclicos utiles como moduladores del factor de necrosis tumoral (tnf) alfa. | |
| EA201890567A1 (ru) | Способ лечения рака | |
| EA201790785A1 (ru) | Производные тетрагидроизохинолина | |
| ZA201904522B (en) | Heterocyclic inhibitors of mct4 | |
| MX382624B (es) | Compuestos farmacéuticos. | |
| EA201692313A1 (ru) | Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ |